Clinical trial · Interventional
Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients
Aspirin Improve Survival of Patients With N2-3 Nasopharyngeal Carcinoma: A Phase 2 Prospective Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nasopharyngeal carcinoma (NPC) is one of the most common maligancies of China. In the era of intensity-modulated radiotherapy (IMRT), the 5-year overall survival (OS) has now reached 85.0% or more. However, even after chemoradiation, the 5-year distant-metastasis rate of patients with N2-3 NPC is still 36.7%. Aspirin is proven in lab and clinical studies to have the abilities of inhibiting the inflammation which could enhance metastasis of breast and colorectal cancers. And before this study, it was discovered that regular aspirin intake might be associated with distant-metastasis-free survival (MFS) and OS independently. So this Phase 2 trial was conducted to validate the impact of aspirin on prognosis of N2-3 NPC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aspirin | Drug | Aspirin | ALIAS |
| Concurrent chemotherapy | Drug | — | UNRESOLVED |
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Controlled Group
- description
- The patients in the Controlled Group are allocated to receive radiotherapy and concurrent chemotherapy.
- interventionNames
- Radiation: Radiotherapy
- Drug: Concurrent chemotherapy
- type
- EXPERIMENTAL
- label
- Experimental Group
- description
- The patients in the Experimental Group are allocated to receive radiotherapy and concurrent chemotherapy plus daily aspirin.
- interventionNames
- Radiation: Radiotherapy
- Drug: Concurrent chemotherapy
- Drug: Aspirin
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologic dianosis of nasopharyngeal carcinoma * Stage of T1-4N2-3M0 (UICC/AJCC classification ver. 7) * 18-70 years old * Karnofsky performance score \> 70 Exclusion Criteria: * Distant metastasis before or during radiotherapy * Severe dysfunctions of liver, kidney, lung, heart of bone marrow which are not fit for radiotherapy * Prior malignancies * Prior history of radiotherapy, chemotherapy or monoclonal antibody therapy * Participation of other drug trials within 3 months * Regular use of aspirin before dianosis * Contraindication or allergy of aspirin * Patients who are considered by the researchers not suitable to participate this trial
References
Publications (0)
Data not yet available